Floatz Rating
CCC52/100
Confidence
Indicative
Sponsor
Universitaire Ziekenhuizen KU Leuven
Modality
Small molecule
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
37Moderate confidence
Detailed axis rationale is planned and will be published soon.
No trial-level evidence is linked to this axis yet.
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · REM Sleep Behavior Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| PE 2I (this asset) | Universitaire Ziekenhuizen KU Leuven | P1/2 | CCC · 52 |
| Ioflupane | Weill Medical College of Cornell University | P4 | BBB |
| 3-IODOBENZYLGUANIDINE (123I) | Mayo Clinic | P4 | BB |
| .Gamma.-Hydroxybutyrate Sodium Salt | Stanford University | P4 | BB |
| Idebenone | Second Affiliated Hospital, School of Medicine, Zhejiang University | P2/3 | B |
| Rasagiline | Second Affiliated Hospital, School of Medicine, Zhejiang University | P2/3 | B |
| Clonazepam | Seoul National University Hospital | P2 | B |
| Terazosin | Cedars-Sinai Medical Center | P2 | CCC |
| Adalimumab | Yale University | P2 | CCC |
+9 more in the REM Sleep Behavior Disorder cohort
Other indications for PE 2I
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Parkinson Disease | — | P1/2 | CC · 44 |
| Amyotrophic Lateral Sclerosis | — | N/A | D · 30 |
| Alzheimer Disease | — | N/A | D · 30 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- IoflupaneWeill Medical College of Cornell UniversityBBB
- 3-IODOBENZYLGUANIDINE (123I)Mayo ClinicBB
- .Gamma.-Hydroxybutyrate Sodium SaltStanford UniversityBB
- IdebenoneSecond Affiliated Hospital, School of Medicine, Zhejiang UniversityB
- RasagilineSecond Affiliated Hospital, School of Medicine, Zhejiang UniversityB
Citation
Floatz Terminal. PE 2I in REM Sleep Behavior Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pe-2i-rem-sleep-behavior-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →